Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Longeveron CEO issues 2026 Letter to Stockholders.
-
Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease
-
Longeveron (LGVN), developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, reported 1Q26 financial results.
-
Kensington, MD, USA and Munich/Martinsried, Germany, March 20, 2026 (GLOBE NEWSWIRE) -- Prodrug of oral amyloid beta aggregation modulator demonstrated improved absorption characteristics, leading...
-
Longeveron reported financial results for the year ended December 31, 2025 and provided a business update. Results from pivotal P2 trial anticipated 3Q26.
-
- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene...
-
Kensington, MD, USA and Munich/Martinsried, Germany, March 05, 2026 (GLOBE NEWSWIRE) -- Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta...
-
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Transposon Therapeutics, a biotechnology company developing therapies for the treatment of neurodegenerative and aging-related diseases, today announced...
-
SYDNEY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the XanaMIA pivotal Alzheimer’s disease (AD) trial’s independent Data Monitoring Committee (DMC) has...
-
Tampa, FL, Jan. 14, 2026 (GLOBE NEWSWIRE) -- A new national survey of Alzheimer’s patients and caregivers reveals widespread gaps in support, communication, and access to emerging diagnostic...